# Annex I – Evaluation checklist

The goal of this checklist is to collect information about a digital COVID certificate system used or planned to be used by a third country. The information is needed for evaluating the options for preparing an equivalence decision following Article 8(2) of the [EU Digital Covid Certificate (EUDCC) Regulation](https://eur-lex.europa.eu/eli/reg/2021/953/oj). An equivalence decision is an implementing act establishing that COVID-19 certificates are issued by a third country in accordance with standards and technological systems that are interoperable with the trust framework and other conditions applicable to the EU Digital COVID Certificate. Find [here all the equivalence decisions already adopted](https://ec.europa.eu/info/publications/commission-implementing-decisions-eu-equivalence-covid-19-certificates-issued-non-eu-countries_en) .

Click the  checkboxes or replace them by **X** for indicating the correct option(s).

Please send the checklist to [EU-DIGITAL-COVID-CERTIFICATE-COMMITTEE@ec.europa.eu](mailto:EU-DIGITAL-COVID-CERTIFICATE-COMMITTEE@ec.europa.eu).

|  |
| --- |
| Each checklist **should** include the following annexes:   * Description/overview of the system architecture * Examples of QR codes and their raw representations * Links to the lists of vaccines or tests |

# Country and entity

Please provide basic information about the country and entity, representative of which is submitting the evaluation checklist.

|  |  |
| --- | --- |
| 1. Country submitting the evaluation checklist |  |
| 1. Name of institution |  |
| 1. Name, Surname |  |
| 1. Function |  |
| 1. Postal address |  |
| 1. Email address |  |
| 1. Phone number |  |
| 1. Name and contact email of the person in charge of the daily operational follow-up of this application (if different from the Representative listed above) |  |
| 1. Contact person (name, email) at the Country’s Embassy in Brussels |  |

# Basic information about the system

|  |  |
| --- | --- |
| 1. Name of the system for which interoperability with EUDCC is suggested |  |
| 1. Countries in which the system is used (list at most 10 countries) |  |
| 1. Total estimated number of countries using the same system |  |
| 1. Current status of the system | In planning  In testing  In production |
| 1. The system is in use or is planned to be used | On a national/federal level  On a regional/state level  On a local level |
| 1. Date since when the system has been in production or date when entry into production is planned |  |
| 1. Other standards used by your national system (eg Smart Health Card, DIVOC, ICAO, etc) |  |

# Technical architecture

|  |  |
| --- | --- |
| 1. The system is fully compliant with technical specifications as consolidated in the following document: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02021D1073-20211225>   The following eHN Guidelines provide further explanations and instructions complementing the adopted Commission Implementing Decisions   * [JSON Schema](https://ec.europa.eu/health/system/files/2021-06/covid-certificate_json_specification_en_0.pdf) for EU Digital COVID Certificates * [Value sets](https://ec.europa.eu/health/system/files/2022-03/eu-dcc-value-sets_en.pdf) * [Volume 1](https://ec.europa.eu/health/system/files/2022-02/digital-covid-certificates_v1_en.pdf): formats and trust management * [Volume 2](https://ec.europa.eu/health/system/files/2022-02/digital-covid-certificates_v2_en_0.pdf): EU Digital COVID Certificate Gateway * [Volume 3](https://ec.europa.eu/health/system/files/2022-02/digital-covid-certificates_v3_en_0.pdf): 2D Barcode Specifications * [Volume 4](https://ec.europa.eu/health/system/files/2022-02/digital-covid-certificates_v4_en_0.pdf): EU Digital COVID Certificate Applications * [Volume 5](https://ec.europa.eu/health/system/files/2022-03/digital-covid-certificate_v5_en.pdf): Public Key Certificate Governance * EU DCC [Validation Rules](https://ec.europa.eu/health/system/files/2022-02/eu-dcc_validation-rules_en.pdf) * A common standardised [set of data to be included in COVID-19 test result certificates](https://ec.europa.eu/health/system/files/2022-04/covid-19_rat_common-list_en.pdf)   All specifications, guidance and reference implementations can be found on the eHealth Network site: <https://ec.europa.eu/health/ehealth/covid-19_en> | Yes  No  If selected No, shortly explain the main differences: |
| 1. Certificates supported by the system | Vaccination certificate  Test certificate  Recovery certificate |
| 1. Certificates contain a QR code encompassing relevant information (personal data, certificate details, metadata), digitally signed and suitable for offline verification.   *Offline verification means that a use of a web application or online queries to the verification system is not required. Verification is based on the check of the digital signature included in the QR code.* | Yes  No  If selected No, shortly explain how verification is conducted: |
| 1. Encoding standard or specification used for constructing the QR code. Provide a link or include the description as an attachment. |  |
| 1. Digital signature algorithms used by the system |  |
| 1. Estimated number of Document Signer Certificates (DSCs) used for signing the QR code contents. |  |
| 1. Estimated number of Country Signing Certificate Authority (CSCA) certificates used for signing the DSCs. |  |
| 1. Type of CSCAs | Only used for health purposes  Used for health and other purposes  Registered in ICAO PKD |

# Information included in certificates

The data is defined in the Annex (Certificate Datasets) of the [EU DCC Regulation](https://EU). All fields are mandatory unless indicated as optional. Empty values are not allowed, except for date of birth that may be empty only in the case it is empty in the holder’s travel documents.

|  |  |
| --- | --- |
| 1. Personal data | name: surname(s) and forename(s), in that order  date of birth  Comments on possible deviations: |
| 1. Vaccination certificate | disease or agent targeted: COVID-19 (SARS-CoV-2 or one of its variants)  COVID-19 vaccine or prophylaxis  COVID-19 vaccine product name  COVID-19 vaccine marketing authorisation holder or manufacturer  number in a series of doses as well as the overall number of doses in the series  date of vaccination, indicating the date of the latest dose received  Member State or third country in which the vaccine was administered  Comments on possible deviations: |
| 1. Test certificate | disease or agent targeted: COVID-19 (SARS-CoV-2 or one of its variants)  the type of test  test name (optional for NAAT test)  test manufacturer (optional for NAAT test)  date and time of the test sample collection  result of the test  testing centre or facility (optional for rapid antigen tests and laboratory-based antigenic assays)  Member State or third country in which the test was carried out  Comments on possible deviations: |
| 1. Recovery certificate | disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants)  date of the holder’s first positive Covid-19 test result  Member State or third country in which test was carried out  certificate issuer  certificate valid from  certificate valid until (not more than 180 days after the date of first positive Covid-19 test result)  Comments on possible deviations: |
| 1. Metadata | certificate issuer  unique certificate identifier  Comments on possible deviations: |
| 1. Any information included in the certificates in addition to the fields listed above |  |

# Vaccines and antigen tests (rapid antigen tests -RATs-, or laboratory-based antigenic assays)

Coding rules are explained in documents

* [Value sets](https://ec.europa.eu/health/sites/health/files/ehealth/docs/digital-green-value-sets_en.pdf)
* [JSON Schema for EU Digital COVID Certificates](https://ec.europa.eu/health/sites/health/files/ehealth/docs/covid-certificate_json_specification_en.pdf)

|  |  |
| --- | --- |
| 1. Please provide the full list of vaccine products and their marketing authorisation holders for which vaccination certificates are currently issued or are planned to be issued in a near future. Kindly specify the **exact** vaccine product names as used in your country.   *Please note that EU Member States must recognise vaccination certificates for vaccines that have received EU-wide authorisation. The recognition of other vaccines depends on each Member State (overview of* [*vaccines accepted*](https://reopen.europa.eu/static/Worldwide_vaccines_reopen_MS%20update_24-March-2022.xlsx) *by EU member states* *and* [*vaccines correspondence table*](https://reopen.europa.eu/static/COVID-19_VACCINES_3rd_countries_v2_24%20March-2022.xlsx) *)* |  |
| 1. Is vaccine information coded exactly following the EU DCC coding rules? | Yes  No, another code system is used  No, names of vaccine product and manufacturer (or marketing authorization holder) are provided as text only  If answered No, please provide further details on coding or text representation: |
| 1. Are test certificates planned to be issued for antigen tests (rapid antigen tests or laboratory-based antigenic assays)? | Yes  No |
| 1. For which antigen tests are certificates planned to be issued?   *Please note that only rapid antigen tests/laboratory-based antigenic assays belonging to the Health Security Committee's common list are in the scope of the system. As a general rule, test certificates for other antigen tests will be rejected, meaning that their holders may be subject to travel restrictions.*  *(skip the question if not applicable)* | Only rapid antigen tests and laboratory-based antigenic assays on the [Health Security Committee's common list](https://covid-19-diagnostics.jrc.ec.europa.eu/devices?manufacturer&text_name&marking&rapid_diag&format&target_type&field-1=HSC%20common%20list%20%28RAT%29&value-1=1&search_method=AND#form_content) (full list or its subset)  Other rapid antigen tests or laboratory-based antigenic assays  If other than HSC-listed antigen tests are used, please indicate which ones: |
| 1. If test certificates are planned to be issued for antigen tests, how the test device is identified?   *Please note that only JRC-compliant coding is supported by the EU DCC system. If another coding or text is used, test certificates for antigen tests will be rejected, meaning that their holders may be subject to travel restrictions.*  *(skip the question if not applicable)* | Using JRC codes (check [all rapid antigen tests and laboratory-based antigenic assays on the Health Security Committee's common list as coded by JRC](https://covid-19-diagnostics.jrc.ec.europa.eu/devices?manufacturer&text_name&marking&rapid_diag&format&target_type&field-1=HSC%20common%20list%20%28RAT%29&value-1=1&search_method=AND#form_content) for more details)  Using another code system  Using text (manufacturer and test name)  If not using JRC codes, please provide further details on coding or text representation: |

# Interoperability options

|  |  |
| --- | --- |
| 1. If the system is not fully compatible/aligned with the EU DCC infrastructure and its specifications, please provide details, and describe how do you intend to achieve full interoperability.   *(skip the question if not applicable)* |  |
| 1. As part of the interoperability scheme, are you considering reciprocity, enabling verification and direct acceptance of EU DCC compliant certificates? | Yes, for all EU/EEA Member States and other countries interoperable with the system  Yes, for all EU/EEA Member States only  No  If answered No, or only a subset of countries is suggested, please explain why: |
| 1. Proposed target date for starting tests |  |
| 1. Proposed target date for launching the interoperability scheme in production |  |